New hope for hard-to-treat lung cancer: drug combo aims to shrink tumors
NCT ID NCT05020769
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug (SI-B001) combined with a standard pill (osimertinib) in people with advanced non-small cell lung cancer that has stopped responding to previous therapies. About 14 adults will receive the combination to see if it can shrink tumors and control the disease. The goal is to find a better treatment option for this tough-to-treat cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center (SYSUCC)
Guangdong, Guangzhou, 510075, China
-
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
-
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?